TY - JOUR
T1 - Platinum(IV) antitumor complexes and their nano-drug delivery
AU - Jia, Chunyan
AU - Deacon, Glen B.
AU - Zhang, Yingjie
AU - Gao, Chuanzhu
N1 - Funding Information:
This review was substantially written during a period of study leave of CG at Monash University and the hospitality of the host institution is acknowledged. This work was supported by the National Natural Science Foundation of China ( NNSFC ) (Nos. 21361014 , 21302074 ) and Yunnan Applied Basic Research Key Projects (Nos. 2018FA047 ) which are gratefully acknowledged.
Funding Information:
This review was substantially written during a period of study leave of CG at Monash University and the hospitality of the host institution is acknowledged. This work was supported by the National Natural Science Foundation of China (NNSFC) (Nos. 21361014, 21302074) and Yunnan Applied Basic Research Key Projects (Nos. 2018FA047) which are gratefully acknowledged.
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2021/2/15
Y1 - 2021/2/15
N2 - Platinum-based anticancer drugs dominate the chemotherapy field for several cancers, but problems such as systemic toxicity and acquired resistance for some primary tumors hamper their clinical applications and therapeutic efficacy. Thus, it is necessary to explore alternative strategies to reduce the side effects and improve the pharmacokinetic profiles of platinum complexes. PtIV complexes are highly promising candidates to overcome some problems of clinically approved platinum-drugs. Reduction to toxic PtII species under the reducing intracellular environment is essential for their anticancer activity. Due to this unique mechanism, PtIV drugs can avoid the destruction by the digestive system to a large extent, making them more acceptable to cancer patients through oral treatment. In addition, the structural characteristics of PtIV drugs are different from traditional PtII drugs, such as cisplatin and carboplatin, which allows them to prevent undesired effects and overcome the resistance of cisplatin analogs. Nano-drug delivery systems have become one of the focus areas of new drug research and development because of their good biocompatibility, large drug loading, accurate tumor targeting and other advantages. This overview briefly analyzes mechanisms underlying platinum biological activity and resistance, and then is concerned with the development of PtIV complexes, especially highlighting combination therapy with nanocarriers. The progress that PtIV complexes and nanotechnology have already made will advance platinum-based chemotherapy and promote the translation to clinical applications.
AB - Platinum-based anticancer drugs dominate the chemotherapy field for several cancers, but problems such as systemic toxicity and acquired resistance for some primary tumors hamper their clinical applications and therapeutic efficacy. Thus, it is necessary to explore alternative strategies to reduce the side effects and improve the pharmacokinetic profiles of platinum complexes. PtIV complexes are highly promising candidates to overcome some problems of clinically approved platinum-drugs. Reduction to toxic PtII species under the reducing intracellular environment is essential for their anticancer activity. Due to this unique mechanism, PtIV drugs can avoid the destruction by the digestive system to a large extent, making them more acceptable to cancer patients through oral treatment. In addition, the structural characteristics of PtIV drugs are different from traditional PtII drugs, such as cisplatin and carboplatin, which allows them to prevent undesired effects and overcome the resistance of cisplatin analogs. Nano-drug delivery systems have become one of the focus areas of new drug research and development because of their good biocompatibility, large drug loading, accurate tumor targeting and other advantages. This overview briefly analyzes mechanisms underlying platinum biological activity and resistance, and then is concerned with the development of PtIV complexes, especially highlighting combination therapy with nanocarriers. The progress that PtIV complexes and nanotechnology have already made will advance platinum-based chemotherapy and promote the translation to clinical applications.
KW - Antitumor
KW - Drug delivery system
KW - Nanoparticles
KW - Platinum(IV) complexes
UR - http://www.scopus.com/inward/record.url?scp=85096864408&partnerID=8YFLogxK
U2 - 10.1016/j.ccr.2020.213640
DO - 10.1016/j.ccr.2020.213640
M3 - Review Article
AN - SCOPUS:85096864408
SN - 0010-8545
VL - 429
JO - Coordination Chemistry Reviews
JF - Coordination Chemistry Reviews
M1 - 213640
ER -